Clinical trials in Limoges – page 3

469 clinical trials in Limoges, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Limoges at a glance

469

clinical trials

Research sites1

Quick filters

469 trials in Limoges

Open in trial search

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ramucirumab
Sponsor:AstraZeneca AB

Contact Research Centre

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Pfizer Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Peripheral arterial occlusive disease+5

Recruiting

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Clopidogrel
Sponsor:Fondation Hopital Saint Joseph

Contact Research Centre

Secondary progressive multiple sclerosis

Recruiting

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational

France

Participants:18–64 years · 65+ years
Substances:Remibrutinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Letrozole
Sponsor:Olema Pharmaceuticals Inc.

Contact Research Centre

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Sponsor:Sumitomo Pharma America Inc.

Contact Research Centre

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational

France

Participants:18–64 years · 65+ years
Substances:LY3437943 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Acute kidney injury

Recruiting

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational

A study testing how well AZD4144 works and how safe it is for adults with acute kidney injury caused by sepsis

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Hepatitis D

Recruiting

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Registered drugNo placebo

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:BJT-778
Sponsor:Mirum Pharmaceuticals Inc.

Contact Research Centre

Parkinson's disease

Recruiting

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational

A study comparing prasinezumab with placebo for people with early-stage Parkinson's disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Prasinezumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Limoges

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma treatments and novel therapies for various cancers. Current trials investigate innovative approaches for colorectal cancer and esophageal squamous cell carcinoma.

Multiple Myeloma Treatment Optimization
Advanced Biliary Tract Cancer Therapy
Breast Cancer Treatment Innovation

Studies are evaluating new combination therapies and maintenance treatments to improve patient outcomes.

02 Neurological Disorders

Critical research into Amyotrophic Lateral Sclerosis (ALS) treatments, testing new therapeutic compounds and combinations to slow disease progression.

ALS Treatment Development
Novel Drug Combinations
Disease Progression Management

Multiple trials are exploring innovative approaches to improve quality of life for ALS patients.

03 Immunology and Transplantation

Advanced research in kidney transplantation and immune-related conditions, including studies on preventing rejection and managing immunosuppression.

Transplant Rejection Prevention
Immunotherapy Developments
Infection Prevention Strategies

Innovative approaches to improve transplant outcomes and manage immune system responses.

Back to France All countries